0001437749-25-018586
SEC filingRevenue grew 11.5% to $241M with 4.6% organic growth; operating income swung to $16.3M as prior year included $274.5M impairment.
Mesa Laboratories, Inc. is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. The company’s purpose is “Protecting the Vulnerable®,” achieved through a customer-focused approach to developing and delivering products and services. Revenue is generated from product sales (consumables and hardware) and services (maintenance, calibration, testing).
The company reports financial performance in four segments: (1) Sterilization and Disinfection Control, which manufactures biological, chemical, and cleaning indicators for assessing sterilization and disinfection processes, along with testing services; (2) Clinical Genomics, which develops and sells genetic analysis tools (MassARRAY system) and consumables for research applications; (3) Biopharmaceutical Development, offering automated protein analysis (Gyrolab) and peptide synthesis (PurePep) solutions; and (4) Calibration Solutions, providing quality control products for measuring parameters like temperature, humidity, and gas flow across various industries. Unallocated corporate expenses are reported in Corporate and Other.
Key product names include Apex and EZTest biological indicators, GKE Clean-Record chemical indicators, the MassARRAY system with SpectroCHIP arrays, Gyrolab xPand and xPlore instruments with Bioaffy consumables, PurePep Symphony and Chorus peptide synthesizers, PurePep EasyClean purification consumables, and Calibration Solutions brands such as DialyGuard, ViewPoint, DataTrace, DryCal, and BGI.
Sales are conducted through direct sales personnel in North America, Europe, and Asia Pacific, and through independent distributors in these and other regions. No single customer accounted for more than 10% of accounts receivable or revenues in fiscal year 2025. Backlog as of March 31, 2025, was approximately $43.2 million, primarily driven by order timing in Clinical Genomics and Sterilization and Disinfection Control.
Competition varies by segment. Sterilization and disinfection products compete on quality, flexibility, and cost effectiveness. Calibration Solutions faces competition in data loggers, especially in Europe, and dialysis meters; torque testing has relatively low competition. Biopharmaceutical Development believes it is one of the leading worldwide suppliers of protein analysis and peptide synthesis equipment. The filing does not name specific competitors.
The company’s strategy centers on organic growth (expanding customer base, product offerings, and pricing) and inorganic growth through acquisitions that complement the existing portfolio. Operational efficiency is pursued through the Mesa Way, a lean-based system with four pillars: Measure what matters, Empower Teams, Sustainably Improve, and Always Learn. The company also emphasizes hiring, developing, and retaining top talent.
As of March 31, 2025, Mesa had 730 employees, including approximately 500 domestic. The workforce is distributed as 359 in manufacturing and quality assurance, 89 in research and development and engineering, 186 in sales and marketing, and 96 in administration. Voluntary employee turnover decreased approximately 2.0 percentage points in fiscal year 2025 compared to the prior year. The company invests in talent acquisition, development, and inclusive hiring practices, and offers competitive compensation including bonuses, stock-based compensation, healthcare, retirement benefits, and paid caregiver leave.
For fiscal year 2025, Mesa Laboratories reported total revenues of $241.0 million, an 11.5% increase from $216.2 million in fiscal 2024. Organic revenue growth, which excludes the GKE acquisition, was 4.6%. The acquisition contributed $15.5 million incremental revenue. Gross profit rose 13.2% to $150.9 million, and gross margin improved 100 basis points to 62.6%, primarily due to $3.4 million lower intangible amortization flowing through cost of revenues following the fiscal 2024 impairment. This was partially offset by higher performance-based compensation. Operating income improved dramatically to $16.3 million from a loss of $272.1 million in fiscal 2024, which included a $274.5 million impairment charge. Excluding impairment, operating expenses increased 3.2%, driven by full-year GKE costs, higher compensation, and professional services. Net loss narrowed to $1.97 million from $254.2 million, impacted by a $11.9 million interest expense (up 108% due to refinancing) and a $7.9 million tax expense (effective rate 133.1% due to valuation allowances).
Management highlighted significant uncertainty from escalating global tariffs, particularly impacting China sales (over $18 million of U.S. exports) and imports from Sweden. They expect potential negative impacts on revenue and margins but are seeking mitigation strategies. The Clinical Genomics and Peptides reporting units remain sensitive to impairment, with fair values exceeding carrying values by 40% and 20%, respectively, as of January 2025. The company has $97.5 million in convertible notes due August 2025 and plans to use cash on hand, revolver draws ($115 million available), and operating cash flow to repay. No formal guidance was provided, but the focus remains on organic growth, operational efficiency, and strategic acquisitions to drive long-term value.
As of March 31, 2025, Mesa Laboratories held $27.3 million in cash and cash equivalents. Total debt stood at $177.9 million, comprising $71.3 million in term loan (net carrying $66.9M), $10.0 million drawn on the revolver, and $97.3 million in convertible senior notes (net of issuance costs). The convertible notes, bearing 1.375% interest and maturing August 15, 2025, are classified as current liabilities. The company also had $115 million available on its $125 million revolver. Shareholders' equity was $159.8 million, with an accumulated deficit of $188.9 million. Inventory decreased to $25.4 million from $32.7 million year-over-year, partly due to amortization of the GKE inventory step-up.
The Notes disclose two material acquisition-related commitments as of March 31, 2025: (1) a $9.3 million GKE acquisition holdback liability (reflected at estimated fair value using Level 3 inputs, ultimately settled in April 2025 for $9.6 million), and (2) a $0.7 million contingent consideration liability related to the Belyntic acquisition, payable upon regulatory patent approval. The company also had $14.7 million in unearned revenues (contract liabilities). Additionally, operating lease liabilities totaled $15.9 million in present value, with future lease payments of $20.0 million through 2031. No other explicit purchase commitments (e.g., inventory or capacity) were disclosed.
Mesa paid dividends totaling $3.5 million ($0.64 per share annually) in fiscal 2025, unchanged from the prior year. The company did not repurchase any shares under its existing buyback authorization (162K shares repurchased cumulatively; program remains active). Capital expenditures were $4.2 million (1.8% of sales). On the debt front, the company borrowed $73.5 million on its credit facility, repaid $44.3 million of debt, and repurchased $75 million principal of its convertible notes for $71.3 million cash (plus fees), recognizing a $2.9 million gain on extinguishment. The new $75 million term loan was drawn to fund the note repurchase. Net debt increased by $74.9 million.
The company reports four segments. For fiscal 2025, Sterilization and Disinfection Control led with $93.4M revenue (39% of total) and $64.7M gross profit. Clinical Genomics generated $47.1M revenue (20% of total) but had the lowest gross margin among segments ($25.7M gross profit). Biopharmaceutical Development contributed $48.7M revenue and $29.9M gross profit, while Calibration Solutions posted $51.7M revenue and $30.6M gross profit. Corporate and Other had negligible revenues and negative gross profit of -$10K. Geographically, U.S. revenues accounted for $116.6M (48% of total), China $25.3M, and all other countries $99.1M. No customer exceeded 10% of revenue.
Mesa Laboratories faces significant exposure to global economic conditions, including elevated interest rates, inflation, and trade tensions. The company explicitly notes that 11% of sales come from China and 41% from other non-domestic countries (primarily Europe), making it vulnerable to tariffs, geopolitical conflicts, and foreign currency fluctuations. Competition is intense, with larger rivals possessing greater resources. The Dialyguard product line, which accounts for approximately one-third of Calibration Solutions revenues and 40% of its gross profit, faces demand risk from technological advancements in dialysis machines.
Supply chain and manufacturing risks are prominent, including reliance on sole or limited source suppliers and potential disruptions from tariffs or geopolitical events. Cybersecurity threats are a key concern, with the company acknowledging past attacks and increasing sophistication. Remote work amplifies these risks. Data privacy regulations (e.g., GDPR, state laws) impose compliance costs and potential fines. Climate change and sustainability regulations could increase costs or disrupt operations.
Mesa's growth strategy depends on acquisitions, which carry risks of underperformance, integration difficulties, and unknown liabilities. Goodwill and intangible assets total $278.6 million, with Clinical Genomics and Peptides reporting units at heightened impairment risk. The company may need additional financing for future acquisitions, potentially diluting shareholders or increasing debt.
The company is subject to extensive FDA and international regulations for its medical devices. Off-label marketing, product modifications requiring new clearances, and product liability suits are material risks. Export controls and government contract regulations add compliance burdens. Anti-corruption laws (FCPA) pose enforcement risks for international operations.
The most pressing financial risk is the $97.5 million in 1.375% convertible senior notes due August 15, 2025. Repayment will require a combination of cash and credit facility draw, increasing interest expense. Foreign currency exposure is unhedged. Tax audits and changes in international tax rules (e.g., OECD BEPS) could increase liabilities. The company's stock price is volatile, and additional equity issuances could dilute shareholders.
The company reported a net loss of $1.97M in FY2025, yet generated strong operating cash flow of $46.8M, indicating high earnings quality due to significant non-cash charges. Key add-backs included $19.1M amortization of intangibles, $13.1M stock-based compensation, and $5.4M depreciation. Working capital changes contributed $7.0M positive cash, driven by a $9.5M increase in accrued liabilities, partly offset by a $2.9M increase in receivables.
Capex of $4.2M was modest relative to operating cash flow, representing a 9% reinvestment rate. This suggests a low capital-intensive business model, allowing ample free cash flow generation for debt reduction and dividends.
Dividends of $3.5M were maintained, while the company used $71.6M to repurchase convertible senior notes and net $29.2M in additional debt repayments, resulting in negative financing cash flow. No share repurchases occurred.
The 2024 period included a $274.5M impairment loss, which made operating cash flow comparison more meaningful on an adjusted basis. The 2025 investing activities lacked major acquisitions, contrasting with $78.7M spent in 2024.